Biotechnology
Page 1 • 3 itemsGain critical insights into global biotech markets. NovaPharmaNews delivers essential intelligence for pharma BD, investors & analysts.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Ankt Drug Promotion Violations
ImmunityBio faces securities lawsuit after FDA warning letter over promotional claims for lead biologic Ankt, impacting IBRX stock from January-March 2026.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Anktiva Claims
ImmunityBio faces securities lawsuit after FDA warning letter regarding executive claims about lead immunotherapy drug Anktiva, impacting investor confidence.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Ankt Drug Claims
ImmunityBio faces securities lawsuit after FDA warning letter regarding executive claims about lead biologic Ankt, affecting investors from Jan-Mar 2026.